Condition
Clinically Significant Prostate Cancer clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Clinically Significant Prostate Cancer clinical trials that are recruiting, at sites in 3 countries (most in Turkey (Türkiye) (2), China (2), United States (1)). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 3Countries
Newest Clinically Significant Prostate Cancer clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Transperineal vs Transrectal Cognitive Fusion Biopsy for Prostate Cancer | — | Ankara, Yenimahalle | Recruiting | Jul 17, 2026 |
| Multi-Modal Imaging and Digital Pathology to Predict Clinically Significant Prostate Cancer | — | Liuzhou, Guangxi | Recruiting | May 29, 2026 |
| Blood exosomal RNA test to diagnose clinically significant prostate cancer | — | Chicago, Illinois and 9 other locations | Recruiting | Mar 25, 2026 |
| Using PSMA PET/CT imaging to help choose which men with low-risk prostate cancer can enter active surveillance | — | Istanbul, Turkey and 9 other locations | Recruiting | Sep 11, 2025 |
All recruiting trials (4)
-
Transperineal vs Transrectal Cognitive Fusion Biopsy for Prostate Cancer
This study tests whether a transperineal cognitive fusion biopsy works as well as the traditional transrectal approach for detecting clinically significant prostate cancer in men with suspicious mpMRI findings.
-
Multi-Modal Imaging and Digital Pathology to Predict Clinically Significant Prostate Cancer
A multi-center study tests a deep learning model that combines MRI, ultrasound, and digital pathology to see if it can predict clinically significant prostate cancer non-invasively and help guide biopsies.
-
Blood exosomal RNA test to diagnose clinically significant prostate cancer
This study will test whether a blood-based exosome RNA signature can detect clinically significant prostate cancer in men with elevated PSA and suspicion for cancer.
-
Using PSMA PET/CT imaging to help choose which men with low-risk prostate cancer can enter active surveillance
The team will test whether delayed Ga-68 PSMA PET/CT scans using the Istanbul PSMA PET/CT Criteria can help decide which men with biopsy-confirmed low-risk prostate cancer can safely choose active surveillance.
Related topics
Quick answers
How many Clinically Significant Prostate Cancer clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in Turkey (Türkiye) (2 trials), China (2 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.